PE firm Ampersand acquires German CDMO Vibalogics

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/mikdam)
(Image: Getty/mikdam)

Related tags: CDMO, Ampersand Capital, PE, acquistion, development, Manufacturing, Gmp, Gene therapy

The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.

Through the acquisition, the middle market private equity (PE) firm will work to expand Vibalogics capabilities to meet the industry’s demand through investments in additional process development and manufacturing capabilities.

The German contract development and manufacturing organization (CDMO) provides services for biopharmaceutical companies working to develop oncolytic viral therapies, gene therapies, and vaccines, specifically focusing on viruses, live bacteria, and aseptic processing.

Vibalogic’s 27,000 square-foot facility in Cuxhaven, Germany has four independent good manufacturing practice (GMP) production suites, and all laboratories meet BSL-2 standards.

David Anderson, general partner at Ampersand explained, “Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company.”

Stefan Bayer, CEO of Vibalogics, said in a statement that with this partnership Vibalogics will also be able to strengthen and expand its position in the US and European markets.

Ampersand’s current portfolio includes other service providers such as Brammer Bio, Avista Pharma, Bioventus, MedPharm, and KeyBiologics.

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars